EA018620B1 - ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1 - Google Patents

ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1 Download PDF

Info

Publication number
EA018620B1
EA018620B1 EA201100698A EA201100698A EA018620B1 EA 018620 B1 EA018620 B1 EA 018620B1 EA 201100698 A EA201100698 A EA 201100698A EA 201100698 A EA201100698 A EA 201100698A EA 018620 B1 EA018620 B1 EA 018620B1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
disease
compound
meta
hydrogen
Prior art date
Application number
EA201100698A
Other languages
English (en)
Russian (ru)
Other versions
EA201100698A1 (ru
Inventor
Герман Кемпен
Даниель Беллюс
Барбара Штэлин
Original Assignee
Сёркомед Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сёркомед Ллк filed Critical Сёркомед Ллк
Publication of EA201100698A1 publication Critical patent/EA201100698A1/ru
Publication of EA018620B1 publication Critical patent/EA018620B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EA201100698A 2008-10-30 2009-10-29 ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1 EA018620B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08167982 2008-10-30
PCT/EP2009/064243 WO2010049466A1 (en) 2008-10-30 2009-10-29 Thienotriazolodiazepine derivatives active on apo a

Publications (2)

Publication Number Publication Date
EA201100698A1 EA201100698A1 (ru) 2011-12-30
EA018620B1 true EA018620B1 (ru) 2013-09-30

Family

ID=40380148

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100698A EA018620B1 (ru) 2008-10-30 2009-10-29 ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1

Country Status (11)

Country Link
US (1) US8569288B2 (pt-PT)
EP (1) EP2362876B1 (pt-PT)
JP (1) JP5490811B2 (pt-PT)
KR (1) KR101633742B1 (pt-PT)
CN (1) CN102292341B (pt-PT)
AU (1) AU2009309691B2 (pt-PT)
BR (1) BRPI0914406A2 (pt-PT)
CA (1) CA2741934C (pt-PT)
EA (1) EA018620B1 (pt-PT)
ES (1) ES2448567T3 (pt-PT)
WO (1) WO2010049466A1 (pt-PT)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2118074T3 (pl) 2007-02-01 2014-06-30 Resverlogix Corp Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego
US9238640B2 (en) 2009-03-18 2016-01-19 Resverlogix Corp. Anti-inflammatory agents
NZ596117A (en) 2009-04-22 2014-10-31 Resverlogix Corp Novel anti-inflammatory agents
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
WO2011143651A1 (en) * 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating metabolism
EP2569434B1 (en) 2010-05-14 2019-09-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating leukemia and related disorders
US9301962B2 (en) 2010-05-14 2016-04-05 Baylor College Of Medicine Male contraceptive compositions and methods of use
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2721031B1 (en) 2011-06-17 2016-01-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
KR20160034379A (ko) 2013-07-25 2016-03-29 다나-파버 캔서 인스티튜트 인크. 전사 인자의 억제제 및 그의 용도
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
EP3099693A4 (en) 2014-01-31 2017-08-16 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
AU2015222805B2 (en) 2014-02-28 2020-05-21 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
EP3157928B1 (en) 2014-06-20 2019-02-13 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
CA2955077A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Dihydropteridinone derivatives and uses thereof
BR112017008714A2 (pt) 2014-10-27 2017-12-19 Tensha Therapeutics Inc inibidores de bromodomínio
CN114984016A (zh) 2015-03-13 2022-09-02 雷斯韦洛吉克斯公司 用于治疗补体相关疾病之组合物及治疗方法
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
PE20181086A1 (es) 2015-09-11 2018-07-05 Dana Farber Cancer Inst Inc Acetamida tienotrizolodiazepinas y usos de las mismas
WO2017044849A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
SG10201913450PA (en) 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
KR20210020889A (ko) 2018-06-13 2021-02-24 디블라이 아게 응축된 트리아제핀 유도체의 제조 및 이의 bet 억제제로서 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
US4960770A (en) * 1987-05-28 1990-10-02 Yoshitomi Pharmaceutical Industries, Ltd. 2-alkyl thieno(triazolo)diazepine compounds and pharmaceutical uses thereof
EP0176927B1 (de) * 1984-10-01 1993-09-08 Boehringer Ingelheim Kg Diazepine enthaltende pharmazeutische Zusammensetzungen mit Plättchen aktivierender Faktor (PAF)-antagonistischer Wirkung
US5854238A (en) * 1995-09-09 1998-12-29 Hoffmann-La Roche Inc. Use of a thienotriazolodiazephine to increase apolipoprotein A-I levels
US6444664B1 (en) * 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
EP0176927B1 (de) * 1984-10-01 1993-09-08 Boehringer Ingelheim Kg Diazepine enthaltende pharmazeutische Zusammensetzungen mit Plättchen aktivierender Faktor (PAF)-antagonistischer Wirkung
US4960770A (en) * 1987-05-28 1990-10-02 Yoshitomi Pharmaceutical Industries, Ltd. 2-alkyl thieno(triazolo)diazepine compounds and pharmaceutical uses thereof
US5854238A (en) * 1995-09-09 1998-12-29 Hoffmann-La Roche Inc. Use of a thienotriazolodiazephine to increase apolipoprotein A-I levels
US6444664B1 (en) * 1997-04-18 2002-09-03 Nederlandse Organisatie Voor Toegepast - Natuurweten Schappelijk Onderzoek (Tno) Method for controlling the plasma level of lipoproteins to treat alzheimeris disease

Also Published As

Publication number Publication date
EA201100698A1 (ru) 2011-12-30
BRPI0914406A2 (pt) 2015-10-20
EP2362876A1 (en) 2011-09-07
WO2010049466A1 (en) 2010-05-06
CN102292341B (zh) 2014-09-10
AU2009309691B2 (en) 2015-04-02
KR101633742B1 (ko) 2016-06-27
JP5490811B2 (ja) 2014-05-14
CA2741934C (en) 2016-09-13
KR20110091523A (ko) 2011-08-11
AU2009309691A1 (en) 2010-05-06
US20110230460A1 (en) 2011-09-22
CA2741934A1 (en) 2010-05-06
EP2362876B1 (en) 2013-12-11
CN102292341A (zh) 2011-12-21
JP2012506896A (ja) 2012-03-22
US8569288B2 (en) 2013-10-29
ES2448567T3 (es) 2014-03-14

Similar Documents

Publication Publication Date Title
EA018620B1 (ru) ПРОИЗВОДНЫЕ ТИЕНОТРИАЗОЛОДИАЗЕПИНА, АКТИВНЫЕ В ОТНОШЕНИИ Apo A1
KR102442747B1 (ko) Ｊａｋ 저해제로서 비피라졸 유도체
KR101290992B1 (ko) Ｃｒｆ 길항제인 시클릭 아미노기로 치환된 피롤로피리미딘및 피롤로피리딘 유도체
JP6745824B2 (ja) 複素環化合物
JP2756004B2 (ja) トリアゾロ―１，４―ジアゼピン系化合物
JP4555476B2 (ja) 縮合アゼピノン型サイクリン依存性キナーゼ阻害物質
JPWO2017069279A1 (ja) 複素環化合物
US20210292340A1 (en) Cell necrosis inhibitor, preparation method therefor and use thereof
TW201311685A (zh) 咪唑並吡啶化合物
SK56195A3 (en) Pyrrolopyrimidine derivatives with pharmacologic effeciency
RU2765718C1 (ru) Замещенное производное дигидропирролопиразола
CZ20031777A3 (cs) Triheterocyklické sloučeniny a léčivo na jejich bázi
CA2917965C (fr) Nouveaux derives d'indole et de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JPH0565288A (ja) 新規なアシルアミノ置換ヘトラゼピン誘導体、その製法及びそれを含有する医薬組成物
JP2001512727A (ja) ５ｈｔ−１受容体のリガンドとしてのニ環式化合物
JP2002020386A (ja) ピラゾロピリジン誘導体
JP7317721B2 (ja) 複素環化合物
KR20130113928A (ko) 3,4-디히드로피롤로[1,2-ａ]피라진-2,8(1Ｈ)-디카르복스아미드 유도체, 그의 제조법 및 그의 치료 용도
KR20220042379A (ko) 키티나제 억제제로서 유용한 치환된 아미노 트리아졸
FR2932482A1 (fr) Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
CA2317515A1 (en) Oxazole derivatives as serotonin-1a receptor agonists
KR20150074131A (ko) 1h-인돌-3-카복스아미드 유도체, 및 p2y12 길항제로서의 그의 용도
EA005071B1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[4,3-e]ДИАЗЕПИНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, И ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ ПРОДУКТОВ
WO2008022747A1 (en) Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents
JP2019528267A (ja) Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ RU